FindTrial
Sign In

Poziotinib Hydrochloride

DRUG2 trials

Sponsors

Spectrum Pharmaceuticals, Inc, M.D. Anderson Cancer Center

Conditions

Breast CancerColorectal CancerGlioblastome MultiformeMetastatic Lung Non-Small Cell CarcinomaSolid TumorStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8

Phase 2

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
TerminatedNCT04172597
Spectrum Pharmaceuticals, IncBreast Cancer, Colorectal Cancer, Glioblastome Multiforme +1
Start: 2019-12-23End: 2022-03-29Updated: 2024-03-13
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
WithdrawnNCT05045404
M.D. Anderson Cancer CenterMetastatic Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8 +1
Start: 2021-06-16End: 2023-02-02Updated: 2023-09-13

Related Papers

Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib
JTO Clinical and Research Reports2020-08-071 citations